Organic compounds -- part of the class 532-570 series – Organic compounds – Four or more ring nitrogens in the bicyclo ring system
Reexamination Certificate
2008-02-15
2011-10-25
Havlin, Robert (Department: 1626)
Organic compounds -- part of the class 532-570 series
Organic compounds
Four or more ring nitrogens in the bicyclo ring system
C514S249000
Reexamination Certificate
active
08044198
ABSTRACT:
Provided herein are novel sirtuin-modulating compounds and methods of use thereof. The sirtuin-modulating compounds may be used for increasing the lifespan of a cell, and treating and/or preventing a wide variety of diseases and disorders including, for example, diseases or disorders related to aging or stress, diabetes, obesity, neurodegenerative diseases, cardiovascular disease, blood clotting disorders, inflammation, cancer, and/or flushing as well as diseases or disorders that would benefit from increased mitochondrial activity. Also provided are compositions comprising a sirtuin-modulating compound in combination with another therapeutic agent.
REFERENCES:
patent: 3517007 (1970-06-01), Kim et al.
patent: 4018932 (1977-04-01), Spicer et al.
patent: 4939133 (1990-07-01), Connor et al.
patent: 6653309 (2003-11-01), Saunders et al.
patent: 7345178 (2008-03-01), Nunes et al.
patent: 7829556 (2010-11-01), Bemis et al.
patent: 2004/0176396 (2004-09-01), Biftu et al.
patent: 2004/0180905 (2004-09-01), Munchhof
patent: 2005/0245539 (2005-11-01), Mendla et al.
patent: 2007/0037809 (2007-02-01), Nunes et al.
patent: 2007/0037810 (2007-02-01), Nunes et al.
patent: 2007/0037827 (2007-02-01), Nunes et al.
patent: 2007/0037865 (2007-02-01), Nunes et al.
patent: 2009/0099170 (2009-04-01), Nunes et al.
patent: 2009/0163476 (2009-06-01), Milburn et al.
patent: 2010/0168084 (2010-07-01), Huber et al.
patent: 1 402 689 (1975-08-01), None
patent: 50-76084 (1975-06-01), None
patent: 52-89689 (1977-07-01), None
patent: 07 291976 (1995-11-01), None
patent: WO-01/27119 (2001-04-01), None
patent: WO-03/007959 (2003-01-01), None
patent: WO-03/011219 (2003-02-01), None
patent: WO-03/028725 (2003-04-01), None
patent: WO-03/028728 (2003-04-01), None
patent: WO-03/042188 (2003-05-01), None
patent: WO-2004/080481 (2004-09-01), None
patent: WO-2005/058884 (2005-06-01), None
patent: WO-2005/069998 (2005-08-01), None
patent: WO-2006053227 (2006-05-01), None
patent: WO-2006094236 (2006-09-01), None
patent: WO-2007019344 (2007-02-01), None
patent: WO-2008106692 (2008-09-01), None
Porcu, et al., “The emerging therapeutic potential of sirtuin-interacting drugs: from cell death to lifespan extension,” TRENDS in Pharmacological Sciences, 26(2):94-103 (2005).
Andreani, et al., “6-(Hydroxyphenyl) Imidazo [2,1-b]Thiazoles as Potential Antiinflammatory Agents: Effects on Human Neutrophil Functions,”Collection of Czechoslovak Chemical Communications, 65:267-279 (2000).
Andreani, et al., “Synthesis and antitubercular activity of imidazol[2,1-b]thiazoles,”European Journal of Medicinal Chemistry, 36:743-746 (2001).
Andreani, et al., “Synthesis and antitumor activity of substituted 3-(5-imidazo[2,1-b]thiazolylmethylene)-2-indolinones,”Anti-Cancer Drug Design, 16:167-174 (2001).
Andreani, et al.,“Thienylimidazo[2,1-b]thiazoles as Inhibitors of Mitochondrial NADH Dehydrogenase,”Journal of Medicinal Chemistry, 38:1090-1097 (1995).
Barchechath, et al., “Inhibitors of Apoptosis in Lymphocytes: Synthesis and Biological Evaluation of Compounds Related to Pifithrin-α,”Journal of Medicinal Chemistry, 48:6409-6422 (2005).
Bienayme and Bouzid et al., “A New Heterocyclic Multicomponent Reaction for the Combinatorial Synthesis of Fused 3-Aminoimidazoles,”Angewandte Chemie International Edition, 37(16):2234-2237 (1998).
Forti, et al., “NADPH-generating system: influence on microsomal mono-oxygenase stability during incubation for the liver-microsomal assay with rat and mouse S9 fractions,”Mutation Research, 129:291-297 (1984).
Freymann, et al., Efficient identification of inhibitors targeting the closed active site conformation of the HPRT fromTrypansoma cruzi, Chemistry and Biology, 7:957-968 (2000).
Gemesi, et al., “Application of LC-MS analysis to the characterisation of the in vitro and in vivo metabolite profiles of RGH-1756 in the rat,”Journal of Pharmaceutical and Biomedical Analysis, 24:877-885 (2001).
Hozien, et al., “An Efficient Route for Synthesis of 5,6-Diphenylimidazo-[2,1-b]thiazoles as Antibacterial Agents,”Journal of Heterocyclic Chemistry, 37:943-949 (2000).
Ikeda, et al., “Functional analysis of four naturally occurring variants of human constitutive androstane receptor,”Molecular Genetics and Metabolism, 86:314-319 (2005).
Jinno, et al., “Identification of Novel Alternative Splice Variants of Human Constitutive Androstane Receptor and Characterization of Their Expression in the Liver,”Molecular Pharmacology, 65(3):496-502 (2004).
Laszlovszky, et al., “Substituted phenoxyalkylpiperazines as dopamine D3receptor ligands,”Pharmazie, 56(4):287-289 (2001).
Lewis, et al., “Levamisole-Resistant Mutants of the NematodeCaenorhabditis elegansAppear to Lack Pharmacological Acetylcholine Receptors,”Neuroscience, 5:967-989 (1980).
Terjeki, et al., “An HPLC/UV method for the determination of RGH-1756 in dog and rat plasma,”Journal of Pharmaceutical and Biomedical Analysis, 24:913-920 (2001).
Yagodinets, et al., “Convenient method for the synthesis of phosphorus-containing heterocyclic systems of imidazo[2,1-b]thiazoles, imidazo[2,1-a]pyridines and quinoxalines,”Zhurnal Obshchei Khimii, 54(12):2789-2790 (1984).
Yueh, et al., “High Volume Bioassays to Assess CYP3A4-Mediated Drug Interactions: Induction and Inhibition in a Single Cell Line,”Drug Metabolism and Disposition, 33(1):38-48 (2005).
Database Chemcats Chemical Abstracts Service, Columbus, OH, US; Jan. 18, 2005, XP002384121 ON's STK199474, STK199472, STK199473, STK180355, STK174405, STK196060, STK115373, STK164162, STK136073, STK164152, STK120473, STK052285—& “Interchim Intermediates” Jan. 18, 2005, Interchim, Montlucon, France, XP002386059.
Blander et al., “SIRT1 Shows No Substrate Specificity in Vitro”, J. Biol. Chem., 180(11):9780-85 (2005).
Borra et al., “Mechanism of Human SIRT1 Activation by Resveratrol”, J. Biol. Chem., 280(17):17187-195 (2005).
Jules L.H. et al., “Derivatives of 3-, 4-, and 5-Phenylsalicylamides” Journal of the American Pharmaceutical Association. 45(5):277-281 (1956).
Kaeberlein et al., “Substrate-specific Activation of Sirtuins by Resveratrol”, J. Biol. Chem., 280(17):17038-45 (2005).
Pacholec et al., “SRT1720, SRT2183 and SRT1460 Do Not Activate Sirt1 with Native Substrates”, FASEB Summer Research Conferences; NAD Metabolism and Signaling, Jun. 21-26, 2009.
Yogi S. et al, “Synthesis of Arylthio-Substitued 3, 8-Diphenyl-1, 2-diazacycloocta-2, 4, 6, 8-te traenes and Their Thermolysis” Bulletin of the Chemical Society of Japan, vol. 60, No. 1, pp. 335-342, XP0022513709, 1987.
Feige et al., “Specific SIRT1 Activation Mimics Low Energy Levels and Protects against Diet-Induced Metabolic Disorders by Enhancing Fat Oxidation,” Cell Metabolism 8:347-358 (2008).
Milne et al., “Small Molecule Activators of SIRT1 as Therapeutics for the Treatment of Type 2 Diabetes”, Nature 450(29):712-16 (2007).
Pacholec et al., “SRT1720, SRT2183, SRT1460, and Resveratrol are not Direct Activators of SIRT1”, JBC Papers in Press, Manuscript M109.088682, Jan. 8, 2010.
Pacholec et al., “SRT1720, SRT2183, SRT1460, and Resveratrol are not Direct Activators of SIRT1”, J. of Bio. Chem., 285(11):8340-8351, Mar. 12, 2010.
Papers of the Week, “A Resveratrol Reversal”, DOI 10.1074/jbc.P109.088682, Mar. 10, 2010 (abstract).
Smith et al., “Small Molecule Activators of SIRT1 Replicate Signaling Pathways Triggered by Calorie Restriction in vivo,” BMC Systems Biology 3:31 pp. 1-14 (2009).
ClinicalTrials.gov Search of SRT2104—List Results http://clinicaltrials.gov/ct2/results?term=srt2104 (retrieved on Jan. 27, 2011).
ClinicalTrials.gov Search of SRT2379—List Results—http://clinicaltrials.gov/ct2/results?term=srt2379 (retrieved on Jan. 27,
Bemis Jean
Disch Jeremy S.
Milne Jill
Ng Pui Yee
Nunes Joseph J.
Havlin Robert
Ropes & Gray LLP
Sirtris Pharmaceuticals, Inc.
LandOfFree
Sirtuin modulating compounds does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Sirtuin modulating compounds, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Sirtuin modulating compounds will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4262114